Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Vitamin K and the synthesis and function of gamma-carboxyglutamic acid

Bruce Furie, MD
Beth A Bouchard, PhD
Barbara C Furie, PhD
Section Editor
Lawrence LK Leung, MD
Deputy Editor
Jennifer S Tirnauer, MD


Vitamin K is a cofactor for the enzymatic conversion of glutamic acid (Glu) residues to gamma-carboxyglutamic acid (Gla) in vitamin K-dependent proteins, via the endoplasmic reticulum resident vitamin K-dependent gamma-glutamyl carboxylase. This carboxylase activity is found in essentially all mammalian tissues, and its reaction product, Gla, has been observed in both vertebrates and invertebrates; both play an important biological role in protein function [1].

The functions of Gla and the vitamin K-dependent biosynthesis of Gla will be discussed here. An overview of the blood coagulation cascade is presented separately. (See "Overview of hemostasis".)


Vitamin K and its association with blood coagulation were initially described in the 1920s and 1930s, following investigation of a hemorrhagic disease of cattle caused by ingestion of spoiled sweet clover [2]. Since then, a number of observations, which will be discussed in detail below, have improved our understanding of the biological role of vitamin K [3]:

Discovery of vitamin K antagonists and their introduction as pharmacologic agents for anticoagulation (ie, the coumarins) [4].

Discovery of Gla in blood clotting proteins [5,6].


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Mar 8, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Vermeer C, De Boer-Van den Berg MA. Vitamin K-dependent carboxylase. Haematologia (Budap) 1985; 18:71.
  2. Roderick LM. A problem in the coagulation of the blood "sweet clover" disease of cattle. Am J Physiol 1931; 96:413.
  3. Dam H. The antihemorrhagic vitamin of the chick. Occurrence and chemical nature. Nature 1935; 135:652.
  4. Campbell HA, Link KP. Studies on the hemorrhagic sweet clover disease IV. The isolation and crystallization of the hemorrhagic agent. J Biol Chem 1941; 138:21.
  5. Stenflo J, Fernlund P, Egan W, Roepstorff P. Vitamin K dependent modifications of glutamic acid residues in prothrombin. Proc Natl Acad Sci U S A 1974; 71:2730.
  6. Nelsestuen GL, Zytkovicz TH, Howard JB. The mode of action of vitamin K. Identification of gamma-carboxyglutamic acid as a component of prothrombin. J Biol Chem 1974; 249:6347.
  7. Esmon CT, Sadowski JA, Suttie JW. A new carboxylation reaction. The vitamin K-dependent incorporation of H-14-CO3- into prothrombin. J Biol Chem 1975; 250:4744.
  8. Sperling R, Furie BC, Blumenstein M, et al. Metal binding properties of gamma-carboxyglutamic acid. Implications for the vitamin K-dependent blood coagulation proteins. J Biol Chem 1978; 253:3898.
  9. Kurachi K, Davie EW. Isolation and characterization of a cDNA coding for human factor IX. Proc Natl Acad Sci U S A 1982; 79:6461.
  10. Jorgensen MJ, Cantor AB, Furie BC, et al. Recognition site directing vitamin K-dependent gamma-carboxylation resides on the propeptide of factor IX. Cell 1987; 48:185.
  11. Furie BC, Ratcliffe JV, Tward J, et al. The gamma-carboxylation recognition site is sufficient to direct vitamin K-dependent carboxylation on an adjacent glutamate-rich region of thrombin in a propeptide-thrombin chimera. J Biol Chem 1997; 272:28258.
  12. Wu SM, Morris DP, Stafford DW. Identification and purification to near homogeneity of the vitamin K-dependent carboxylase. Proc Natl Acad Sci U S A 1991; 88:2236.
  13. Wu SM, Cheung WF, Frazier D, Stafford DW. Cloning and expression of the cDNA for human gamma-glutamyl carboxylase. Science 1991; 254:1634.
  14. Soriano-Garcia M, Padmanabhan K, de Vos AM, Tulinsky A. The Ca2+ ion and membrane binding structure of the Gla domain of Ca-prothrombin fragment 1. Biochemistry 1992; 31:2554.
  15. Dowd P, Hershline R, Ham SW, Naganathan S. Vitamin K and energy transduction: a base strength amplification mechanism. Science 1995; 269:1684.
  16. Sugiura I, Furie B, Walsh CT, Furie BC. Propeptide and glutamate-containing substrates bound to the vitamin K-dependent carboxylase convert its vitamin K epoxidase function from an inactive to an active state. Proc Natl Acad Sci U S A 1997; 94:9069.
  17. Friedman PA, Shia MA, Gallop PM, Griep AE. Vitamin K-dependent gamma-carbon-hydrogen bond cleavage and nonmandatory concurrent carboxylation of peptide-bound glutamic acid residues. Proc Natl Acad Sci U S A 1979; 76:3126.
  18. Morris DP, Soute BA, Vermeer C, Stafford DW. Characterization of the purified vitamin K-dependent gamma-glutamyl carboxylase. J Biol Chem 1993; 268:8735.
  19. Mack DO, Suen ET, Girardot JM, et al. Soluble enzyme system for vitamin K-dependent carboxylation. J Biol Chem 1976; 251:3269.
  20. Friedman PA, Shia M. Some characteristics of a vitamin K-dependent carboxylating system from rat liver microsomes. Biochem Biophys Res Commun 1976; 70:647.
  21. Suttie JW, Lehrman SR, Geweke LO, et al. Vitamin K-dependent carboxylase: requirements for carboxylation of soluble peptide and substrate specificity. Biochem Biophys Res Commun 1979; 86:500.
  22. Canfield LM, Sinsky TA, Suttie JW. Vitamin K-dependent carboxylase: purification of the rat liver microsomal enzyme. Arch Biochem Biophys 1980; 202:515.
  23. Canfield LM. Vitamin K-dependent oxygenase/carboxylase; differential inactivation by sulfhydryl reagents. Biochem Biophys Res Commun 1987; 148:184.
  24. Bouchard BA, Furie B, Furie BC. Glutamyl substrate-induced exposure of a free cysteine residue in the vitamin K-dependent gamma-glutamyl carboxylase is critical for vitamin K epoxidation. Biochemistry 1999; 38:9517.
  25. Tie J, Wu SM, Jin D, et al. A topological study of the human gamma-glutamyl carboxylase. Blood 2000; 96:973.
  26. Pudota BN, Miyagi M, Hallgren KW, et al. Identification of the vitamin K-dependent carboxylase active site: Cys-99 and Cys-450 are required for both epoxidation and carboxylation. Proc Natl Acad Sci U S A 2000; 97:13033.
  27. Bandyopadhyay PK, Garrett JE, Shetty RP, et al. gamma -Glutamyl carboxylation: An extracellular posttranslational modification that antedates the divergence of molluscs, arthropods, and chordates. Proc Natl Acad Sci U S A 2002; 99:1264.
  28. Tie JK, Mutucumarana VP, Straight DL, et al. Determination of disulfide bond assignment of human vitamin K-dependent gamma-glutamyl carboxylase by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. J Biol Chem 2003; 278:45468.
  29. Rishavy MA, Pudota BN, Hallgren KW, et al. A new model for vitamin K-dependent carboxylation: the catalytic base that deprotonates vitamin K hydroquinone is not Cys but an activated amine. Proc Natl Acad Sci U S A 2004; 101:13732.
  30. Tie JK, Jin DY, Loiselle DR, et al. Chemical modification of cysteine residues is a misleading indicator of their status as active site residues in the vitamin K-dependent gamma-glutamyl carboxylation reaction. J Biol Chem 2004; 279:54079.
  31. Kuliopulos A, Hubbard BR, Lam Z, et al. Dioxygen transfer during vitamin K dependent carboxylase catalysis. Biochemistry 1992; 31:7722.
  32. Wood GM, Suttie JW. Vitamin K-dependent carboxylase. Stoichiometry of vitamin K epoxide formation, gamma-carboxyglutamyl formation, and gamma-glutamyl-3H cleavage. J Biol Chem 1988; 263:3234.
  33. Knobloch JE, Suttie JW. Vitamin K-dependent carboxylase. Control of enzyme activity by the "propeptide" region of factor X. J Biol Chem 1987; 262:15334.
  34. Li S, Furie BC, Furie B, Walsh CT. The propeptide of the vitamin K-dependent carboxylase substrate accelerates formation of the gamma-glutamyl carbanion intermediate. Biochemistry 1997; 36:6384.
  35. Suttie JW. Vitamin K-dependent carboxylase. Annu Rev Biochem 1985; 54:459.
  36. Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427:537.
  37. Li T, Chang CY, Jin DY, et al. Identification of the gene for vitamin K epoxide reductase. Nature 2004; 427:541.
  38. Wallin R, Martin LF. Warfarin poisoning and vitamin K antagonism in rat and human liver. Design of a system in vitro that mimics the situation in vivo. Biochem J 1987; 241:389.
  39. Spohn G, Kleinridders A, Wunderlich FT, et al. VKORC1 deficiency in mice causes early postnatal lethality due to severe bleeding. Thromb Haemost 2009; 101:1044.
  40. Goodstadt L, Ponting CP. Vitamin K epoxide reductase: homology, active site and catalytic mechanism. Trends Biochem Sci 2004; 29:289.
  41. Singh AK, Bhattacharyya-Pakrasi M, Pakrasi HB. Identification of an atypical membrane protein involved in the formation of protein disulfide bonds in oxygenic photosynthetic organisms. J Biol Chem 2008; 283:15762.
  42. Dutton RJ, Boyd D, Berkmen M, Beckwith J. Bacterial species exhibit diversity in their mechanisms and capacity for protein disulfide bond formation. Proc Natl Acad Sci U S A 2008; 105:11933.
  43. Li W, Schulman S, Dutton RJ, et al. Structure of a bacterial homologue of vitamin K epoxide reductase. Nature 2010; 463:507.
  44. Schulman S, Wang B, Li W, Rapoport TA. Vitamin K epoxide reductase prefers ER membrane-anchored thioredoxin-like redox partners. Proc Natl Acad Sci U S A 2010; 107:15027.
  45. Schulman S, Furie B. How I treat poisoning with vitamin K antagonists. Blood 2015; 125:438.
  46. Park BK, Choonara IA, Haynes BP, et al. Abnormal vitamin K metabolism in the presence of normal clotting factor activity in factory workers exposed to 4-hydroxycoumarins. Br J Clin Pharmacol 1986; 21:289.
  47. Choonara IA, Malia RG, Haynes BP, et al. The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin. Br J Clin Pharmacol 1988; 25:1.
  48. Cushman M, Booth SL, Possidente CJ, et al. The association of vitamin K status with warfarin sensitivity at the onset of treatment. Br J Haematol 2001; 112:572.
  49. Kamali F, Edwards C, Butler TJ, Wynne HA. The influence of (R)- and (S)-warfarin, vitamin K and vitamin K epoxide upon warfarin anticoagulation. Thromb Haemost 2000; 84:39.
  50. Brenner B. Hereditary deficiency of vitamin K-dependent coagulation factors. Thromb Haemost 2000; 84:935.
  51. Pauli RM, Lian JB, Mosher DF, Suttie JW. Association of congenital deficiency of multiple vitamin K-dependent coagulation factors and the phenotype of the warfarin embryopathy: clues to the mechanism of teratogenicity of coumarin derivatives. Am J Hum Genet 1987; 41:566.
  52. Oldenburg J, von Brederlow B, Fregin A, et al. Congenital deficiency of vitamin K dependent coagulation factors in two families presents as a genetic defect of the vitamin K-epoxide-reductase-complex. Thromb Haemost 2000; 84:937.
  53. Marchetti G, Caruso P, Lunghi B, et al. Vitamin K-induced modification of coagulation phenotype in VKORC1 homozygous deficiency. J Thromb Haemost 2008; 6:797.
  54. Bodin L, Horellou MH, Flaujac C, et al. A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance. J Thromb Haemost 2005; 3:1533.
  55. Loebstein R, Dvoskin I, Halkin H, et al. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood 2007; 109:2477.
  56. Wilms EB, Touw DJ, Conemans JM, et al. A new VKORC1 allelic variant (p.Trp59Arg) in a patient with partial resistance to acenocoumarol and phenprocoumon. J Thromb Haemost 2008; 6:1224.
  57. Peoc'h K, Pruvot S, Gourmel C, et al. A new VKORC1 mutation leading to an isolated resistance to fluindione. Br J Haematol 2009; 145:841.
  58. Wang Y, Zhang W, Zhang Y, et al. VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection). Circulation 2006; 113:1615.
  59. Price PA, Fraser JD, Metz-Virca G. Molecular cloning of matrix Gla protein: implications for substrate recognition by the vitamin K-dependent gamma-carboxylase. Proc Natl Acad Sci U S A 1987; 84:8335.
  60. Hubbard BR, Ulrich MM, Jacobs M, et al. Vitamin K-dependent carboxylase: affinity purification from bovine liver by using a synthetic propeptide containing the gamma-carboxylation recognition site. Proc Natl Acad Sci U S A 1989; 86:6893.
  61. Tward JD, Furie BC, Bouchard BA, et al. Other amino acids than phenylalanine at position 16 in the carboxylation recognition site in the prothrombin propeptide can support gamma-carboxylation. Blood 1997; 90(Suppl 1):291a.
  62. Huber P, Schmitz T, Griffin J, et al. Identification of amino acids in the gamma-carboxylation recognition site on the propeptide of prothrombin. J Biol Chem 1990; 265:12467.
  63. Chu K, Wu SM, Stanley T, et al. A mutation in the propeptide of Factor IX leads to warfarin sensitivity by a novel mechanism. J Clin Invest 1996; 98:1619.
  64. Oldenburg J, Quenzel EM, Harbrecht U, et al. Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy. Br J Haematol 1997; 98:240.
  65. Oldenburg J, Kriz K, Wuillemin WA, et al. Genetic predisposition to bleeding during oral anticoagulant therapy: evidence for common founder mutations (FIXVal-10 and FIXThr-10) and an independent CpG hotspot mutation (FIXThr-10). Thromb Haemost 2001; 85:454.
  66. Kristensen SR. Warfarin treatment of a patient with coagulation factor IX propeptide mutation causing warfarin hypersensitivity. Blood 2002; 100:2676.
  67. Presnell SR, Stafford DW. The vitamin K-dependent carboxylase. Thromb Haemost 2002; 87:937.
  68. Rehemtulla A, Roth DA, Wasley LC, et al. In vitro and in vivo functional characterization of bovine vitamin K-dependent gamma-carboxylase expressed in Chinese hamster ovary cells. Proc Natl Acad Sci U S A 1993; 90:4611.
  69. Kuo WL, Stafford DW, Cruces J, et al. Chromosomal localization of the gamma-glutamyl carboxylase gene at 2p12. Genomics 1995; 25:746.
  70. Lin PJ, Jin DY, Tie JK, et al. The putative vitamin K-dependent gamma-glutamyl carboxylase internal propeptide appears to be the propeptide binding site. J Biol Chem 2002; 277:28584.
  71. Mutucumarana VP, Acher F, Straight DL, et al. A conserved region of human vitamin K-dependent carboxylase between residues 393 and 404 is important for its interaction with the glutamate substrate. J Biol Chem 2003; 278:46488.
  72. Brenner B, Sánchez-Vega B, Wu SM, et al. A missense mutation in gamma-glutamyl carboxylase gene causes combined deficiency of all vitamin K-dependent blood coagulation factors. Blood 1998; 92:4554.
  73. Spronk HM, Farah RA, Buchanan GR, et al. Novel mutation in the gamma-glutamyl carboxylase gene resulting in congenital combined deficiency of all vitamin K-dependent blood coagulation factors. Blood 2000; 96:3650.
  74. Rost S, Fregin A, Koch D, et al. Compound heterozygous mutations in the gamma-glutamyl carboxylase gene cause combined deficiency of all vitamin K-dependent blood coagulation factors. Br J Haematol 2004; 126:546.
  75. Soute BA, Ulrich MM, Watson AD, et al. Congenital deficiency of all vitamin K-dependent blood coagulation factors due to a defective vitamin K-dependent carboxylase in Devon Rex cats. Thromb Haemost 1992; 68:521.
  76. Zhu A, Sun H, Raymond RM Jr, et al. Fatal hemorrhage in mice lacking gamma-glutamyl carboxylase. Blood 2007; 109:5270.
  77. Mousallem M, Spronk HM, Sacy R, et al. Congenital combined deficiencies of all vitamin K-dependent coagulation factors. Thromb Haemost 2001; 86:1334.
  78. Soute BA, Jin DY, Spronk HM, et al. Characteristics of recombinant W501S mutated human gamma-glutamyl carboxylase. J Thromb Haemost 2004; 2:597.
  79. Bristol JA, Ratcliffe JV, Roth DA, et al. Biosynthesis of prothrombin: intracellular localization of the vitamin K-dependent carboxylase and the sites of gamma-carboxylation. Blood 1996; 88:2585.
  80. Wasley LC, Rehemtulla A, Bristol JA, Kaufman RJ. PACE/furin can process the vitamin K-dependent pro-factor IX precursor within the secretory pathway. J Biol Chem 1993; 268:8458.
  81. Blanchard RA, Furie BC, Kruger SF, et al. Immunoassays of human prothrombin species which correlate with functional coagulant activities. J Lab Clin Med 1983; 101:242.
  82. Ratcliffe JV, Furie B, Furie BC. The importance of specific gamma-carboxyglutamic acid residues in prothrombin. Evaluation by site-specific mutagenesis. J Biol Chem 1993; 268:24339.
  83. Zhang L, Jhingan A, Castellino FJ. Role of individual gamma-carboxyglutamic acid residues of activated human protein C in defining its in vitro anticoagulant activity. Blood 1992; 80:942.
  84. Zhang L, Castellino FJ. The contributions of individual gamma-carboxyglutamic acid residues in the calcium-dependent binding of recombinant human protein C to acidic phospholipid vesicles. J Biol Chem 1993; 268:12040.
  85. Jhingan A, Zhang L, Christiansen WT, Castellino FJ. The activities of recombinant gamma-carboxyglutamic-acid-deficient mutants of activated human protein C toward human coagulation factor Va and factor VIII in purified systems and in plasma. Biochemistry 1994; 33:1869.
  86. Freedman SJ, Furie BC, Furie B, Baleja JD. Structure of the calcium ion-bound gamma-carboxyglutamic acid-rich domain of factor IX. Biochemistry 1995; 34:12126.
  87. Huang M, Furie BC, Furie B. Crystal structure of the calcium-stabilized human factor IX Gla domain bound to a conformation-specific anti-factor IX antibody. J Biol Chem 2004; 279:14338.
  88. Shikamoto Y, Morita T, Fujimoto Z, Mizuno H. Crystal structure of Mg2+- and Ca2+-bound Gla domain of factor IX complexed with binding protein. J Biol Chem 2003; 278:24090.
  89. Banner DW, D'Arcy A, Chène C, et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 1996; 380:41.
  90. Christiansen WT, Jalbert LR, Robertson RM, et al. Hydrophobic amino acid residues of human anticoagulation protein C that contribute to its functional binding to phospholipid Vesicles. Biochemistry 1995; 34:10376.
  91. Sunnerhagen M, Forsén S, Hoffrén AM, et al. Structure of the Ca(2+)-free Gla domain sheds light on membrane binding of blood coagulation proteins. Nat Struct Biol 1995; 2:504.
  92. Freedman SJ, Blostein MD, Baleja JD, et al. Identification of the phospholipid binding site in the vitamin K-dependent blood coagulation protein factor IX. J Biol Chem 1996; 271:16227.
  93. McDonald JF, Shah AM, Schwalbe RA, et al. Comparison of naturally occurring vitamin K-dependent proteins: correlation of amino acid sequences and membrane binding properties suggests a membrane contact site. Biochemistry 1997; 36:5120.
  94. Huang M, Rigby AC, Morelli X, et al. Structural basis of membrane binding by Gla domains of vitamin K-dependent proteins. Nat Struct Biol 2003; 10:751.
  95. Rodríguez Y, Mezei M, Osman R. The PT1-Ca2+ Gla domain binds to a membrane through two dipalmitoylphosphatidylserines. A computational study. Biochemistry 2008; 47:13267.
  96. Ducy P, Desbois C, Boyce B, et al. Increased bone formation in osteocalcin-deficient mice. Nature 1996; 382:448.
  97. Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386:78.
  98. Yao Y, Shahbazian A, Boström KI. Proline and gamma-carboxylated glutamate residues in matrix Gla protein are critical for binding of bone morphogenetic protein-4. Circ Res 2008; 102:1065.
  99. Schurgers LJ, Spronk HM, Skepper JN, et al. Post-translational modifications regulate matrix Gla protein function: importance for inhibition of vascular smooth muscle cell calcification. J Thromb Haemost 2007; 5:2503.
  100. Manfioletti G, Brancolini C, Avanzi G, Schneider C. The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade. Mol Cell Biol 1993; 13:4976.
  101. Nakano T, Kawamoto K, Kishino J, et al. Requirement of gamma-carboxyglutamic acid residues for the biological activity of Gas6: contribution of endogenous Gas6 to the proliferation of vascular smooth muscle cells. Biochem J 1997; 323 ( Pt 2):387.
  102. Kulman JD, Harris JE, Haldeman BA, Davie EW. Primary structure and tissue distribution of two novel proline-rich gamma-carboxyglutamic acid proteins. Proc Natl Acad Sci U S A 1997; 94:9058.
  103. Kulman JD, Harris JE, Xie L, Davie EW. Identification of two novel transmembrane gamma-carboxyglutamic acid proteins expressed broadly in fetal and adult tissues. Proc Natl Acad Sci U S A 2001; 98:1370.
  104. Xu S, Han JC, Morales A, et al. Characterization of 11p14-p12 deletion in WAGR syndrome by array CGH for identifying genes contributing to mental retardation and autism. Cytogenet Genome Res 2008; 122:181.
  105. Price PA, Williamson MK. Substrate recognition by the vitamin K-dependent gamma-glutamyl carboxylase: identification of a sequence homology between the carboxylase and the carboxylase recognition site in the substrate. Protein Sci 1993; 2:1987.
  106. Berkner KL, Pudota BN. Vitamin K-dependent carboxylation of the carboxylase. Proc Natl Acad Sci U S A 1998; 95:466.
  107. Yin ZF, Huang ZF, Cui J, et al. Prothrombotic phenotype of protein Z deficiency. Proc Natl Acad Sci U S A 2000; 97:6734.
  108. Han X, Fiehler R, Broze GJ Jr. Isolation of a protein Z-dependent plasma protease inhibitor. Proc Natl Acad Sci U S A 1998; 95:9250.
  109. Han X, Fiehler R, Broze GJ Jr. Characterization of the protein Z-dependent protease inhibitor. Blood 2000; 96:3049.
  110. Van de Water N, Tan T, Ashton F, et al. Mutations within the protein Z-dependent protease inhibitor gene are associated with venous thromboembolic disease: a new form of thrombophilia. Br J Haematol 2004; 127:190.
  111. Rezaie AR, Bae JS, Manithody C, et al. Protein Z-dependent protease inhibitor binds to the C-terminal domain of protein Z. J Biol Chem 2008; 283:19922.
  112. Broze GJ Jr. Protein-Z and thrombosis. Lancet 2001; 357:900.
  113. Broze GJ Jr. Protein Z-dependent regulation of coagulation. Thromb Haemost 2001; 86:8.
  114. Gris JC, Amadio C, Mercier E, et al. Anti-protein Z antibodies in women with pathologic pregnancies. Blood 2003; 101:4850.
  115. Corral J, González-Conejero R, Hernández-Espinosa D, Vicente V. Protein Z/Z-dependent protease inhibitor (PZ/ZPI) anticoagulant system and thrombosis. Br J Haematol 2007; 137:99.
  116. Zhang J, Tu Y, Lu L, et al. Protein Z-dependent protease inhibitor deficiency produces a more severe murine phenotype than protein Z deficiency. Blood 2008; 111:4973.
  117. Sofi F, Cesari F, Abbate R, et al. A meta-analysis of potential risks of low levels of protein Z for diseases related to vascular thrombosis. Thromb Haemost 2010; 103:749.
  118. Kemkes-Matthes B, Nees M, Kühnel G, et al. Protein Z influences the prothrombotic phenotype in Factor V Leiden patients. Thromb Res 2002; 106:183.
  119. Kemkes-Matthes B, Matthes KJ, Souri M, et al. R255h amino acid substitution of protein Z identified in patients with factor V Leiden mutation. Br J Haematol 2005; 128:248.
  120. Gris JC, Quéré I, Dechaud H, et al. High frequency of protein Z deficiency in patients with unexplained early fetal loss. Blood 2002; 99:2606.
  121. Corral J, González-Conejero R, Soria JM, et al. A nonsense polymorphism in the protein Z-dependent protease inhibitor increases the risk for venous thrombosis. Blood 2006; 108:177.
  122. Vasse M, Guegan-Massardier E, Borg JY, et al. Frequency of protein Z deficiency in patients with ischaemic stroke. Lancet 2001; 357:933.
  123. Kobelt K, Biasiutti FD, Mattle HP, et al. Protein Z in ischaemic stroke. Br J Haematol 2001; 114:169.
  124. Mushunje A, Zhou A, Huntington JA, et al. Antithrombin 'DREUX' (Lys 114Glu): a variant with complete loss of heparin affinity. Thromb Haemost 2002; 88:436.
  125. Ayoub N, Esposito G, Barete S, et al. Protein Z deficiency in antiphospholipid-negative Sneddon's syndrome. Stroke 2004; 35:1329.
  126. Sofi F, Cesari F, Pratesi G, et al. Low protein Z levels in patients with peripheral arterial disease. Thromb Haemost 2007; 98:1114.
  127. Nowak-Göttl U, Fröhlich B, Thedieck S, et al. Association of the protein Z ATG haplotype with symptomatic nonvascular stroke or thromboembolism in white children: a family-based cohort study. Blood 2009; 113:2336.
  128. Sofi F, Cesari F, Tu Y, et al. Protein Z-dependent protease inhibitor and protein Z in peripheral arterial disease patients. J Thromb Haemost 2009; 7:731.
  129. Steffano B, Forastiero R, Martinuzzo M, Kordich L. Low plasma protein Z levels in patients with antiphospholipid antibodies. Blood Coagul Fibrinolysis 2001; 12:411.
  130. McColl MD, Deans A, Maclean P, et al. Plasma protein Z deficiency is common in women with antiphospholipid antibodies. Br J Haematol 2003; 120:913.
  131. Viegas CS, Simes DC, Laizé V, et al. Gla-rich protein (GRP), a new vitamin K-dependent protein identified from sturgeon cartilage and highly conserved in vertebrates. J Biol Chem 2008; 283:36655.